We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Novel drug therapy of acute hepatic failure induced in rats by a combination of tadalafil and Lepidium sativum.
- Authors
Sabra, Mahmoud S.; Mohammed, Ahmed A.; Hassanein, Khaled M. Ahmed; Ahmed, Ahmed A. N.; Hassan, Dalia; Abdel-lah, Ebtsam S.
- Abstract
Background: Hepatocyte death and a systemic inflammatory response are the outcome of a complex chain of events mediated by numerous inflammatory cells and chemical mediators. The point of this study was to find out if tadalafil and/or Lepidium sativum (L. sativum) could help people who have been exposed to carbon tetrachloride (CCL4) and are experiencing acute moderate liver failure. This was especially true when the two were used together. Method and materials: To cause mild liver failure 24 h before sacrifice, a single oral dosage of CCL4 (2.5 mL/kg b.w.) (50% in olive oil) was utilized. Furthermore, immunohistochemical expression of nuclear factor kappa B (NF-κB) as well as histological abnormalities were performed on liver tissue. Results: The results showed that tadalafil and/or L. sativum, especially in combination, performed well to cure acute mild liver failure caused by CCL4. This was demonstrated by a decrease in NF-κB expression in the liver tissue and an improvement in organ damage markers observed in the blood and liver tissues. Furthermore, such therapy reduced interleukin1 beta (IL-1β) and tumor necrosis factor-alpha (TNF-α) levels in the liver tissue. It's worth noting that the tested combination resulted in greater liver improvement. Conclusions: According to the findings, tadalafil and L. sativum, particularly in combination, have the ability to protect the liver from the negative effects of CCL4 exposure. Because of its capacity to improve liver function, restore redox equilibrium, and decrease inflammatory mediators, it is a prospective option for mitigating the negative effects of common environmental pollutants such as CCL4.
- Subjects
DRUG efficacy; ALKALINE phosphatase; GAMMA-glutamyltransferase; LIVER function tests; STATISTICS; COMBINATION drug therapy; BLOOD proteins; ANIMAL experimentation; IMMUNOHISTOCHEMISTRY; ONE-way analysis of variance; NF-kappa B; INTERLEUKIN-1; SUPEROXIDE dismutase; RATS; OXIDATIVE stress; SERUM albumin; TUMOR necrosis factors; RESEARCH funding; DESCRIPTIVE statistics; TADALAFIL; PLANT extracts; INFLAMMATORY mediators; DATA analysis; DATA analysis software; ACUTE diseases; LIVER failure; ASPARTATE aminotransferase; ALANINE aminotransferase; BILIRUBIN; LIPID peroxidation (Biology); GLUTATHIONE peroxidase; PHARMACODYNAMICS; EVALUATION
- Publication
BMC Complementary Medicine & Therapies, 2024, Vol 24, Issue 1, p1
- ISSN
2662-7671
- Publication type
Article
- DOI
10.1186/s12906-024-04406-4